These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9723327

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
    Fabrega AJ, Roy G, Reynolds L, Corwin C, Hunsicker L.
    Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Immunosuppression (Neoral vs Sandimmune) in pediatric kidney transplantation.
    Holm A, Vicente A, Soberanes A, Lagunas J, Espinosa A, Diliz H, Calderón M, Zarate A, Madrazo M.
    Transplant Proc; 1997 Jun; 29(1-2):300-2. PubMed ID: 9123006
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Improvement in correlation between oral dose of cyclosporine and cyclosporinemia after substitution of conventional cyclosporine by Neoral cyclosporine in 296 liver transplant patients.
    Bilbao I, Parrilla P, Rimola A, Figueras J, Fabrega E, Gomez M, De Vicente E, Margarit C.
    Transplant Proc; 1998 Aug; 30(5):1833-7. PubMed ID: 9723300
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB, Martin JE, Schroeder TJ, First MR.
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract] [Full Text] [Related]

  • 38. Use of cyclosporine MEPC (Neoral) in heart transplant recipients.
    Fukushima N, Ohtake S, Sawa Y, Nishimura M, Kobayashi Y, Shirakura R, Nakata S, Matsuda H.
    Transplant Proc; 1998 Nov; 30(7):3337-8. PubMed ID: 9838473
    [No Abstract] [Full Text] [Related]

  • 39. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.
    Serafinowicz A, Gaciong Z, Majchrzak J, Baczkowska T, Nowacka E, Gradowska L, Rowiński W, Lao M.
    Transplant Proc; 1997 Nov; 29(1-2):277-9. PubMed ID: 9122994
    [No Abstract] [Full Text] [Related]

  • 40. Induction therapy with cyclosporine and without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A, Fagiuoli S, Sisson S, Zuhdi N, Cooper DK.
    Transplant Proc; 1994 Oct; 26(5):2749. PubMed ID: 7940864
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.